Thomas J. Schiessle
EUR 190.00 For Business Accounts Only

COVID-19-Einschränkungen nur im Randsegment

Im Q1/20 haben sich die KPI`s „planmäßig“ entwickelt, weil „Planverluste“ aus dem Geschäftsbereich „Advanced Technologies“ - „AT“ belasteten; während der Kernmarkt und somit die Segmente PPG und P&D wuchsen. Der Konzernumsatz insgesamt sank im Q1/20 auf € 304 Mio. (nom. -1,5 %; in CC: -1,8 %); das adj. EBITDA sank organisch um 10% auf € 51,1 Mio.

COVID-19-Einschränkungen betreffen nur Randaktivitäten, die Kosmetik-Anwendungen, ansonsten wird hochausgelastet produziert. Der neue Vorstand ist trotz COVID-19 weiterhin ist trotz COVID-19 weiterhin optimistisch. Er hatte 2019 Wachstumsinitiativen gestartet und will und muss 2020 „liefern“.

Gerresheimer AG

Gerresheimer is a holding company. Through its subsidiaries, Co. manufactures glass and plastic products for the pharma and healthcare industry. Co.'s operates in three divisions: Plastics & Devices, which its product portfolio includes products for the administration of medicines, such as insulin pens, inhalers, and prefillable syringes; Primary Packaging Glass, which produces glass primary packaging for medicines and cosmetics, such as pharma jars, ampoules, injection vials, cartridges, perfume flacons, and cream jars; and Life Science Research, which produces laboratory glassware for research, development, and analytics, such as beakers, Erlenmeyer flasks, and measuring cylinders.


EQUI.TS GmbH is an innovative, equity research boutique based in Frankfurt (Germany). It is operated by its original founders and has established a reputation as a quality research provider over a period of more than 10 years. Although it generally does not focus on any particular branch of industry, its analyses often revolve around technology and growth stocks.

Thomas J. Schiessle

Other Reports on these Companies
Other Reports from EQUITS GmbH
Other Reports from these Analysts

ResearchPool Subscriptions

Get the most out of your insights

Get in touch